Freshfields Bruckhaus Deringer and CMS have advised Advent International and its European medicines producer Zentiva on Zentiva’s acquisition of the Central and Eastern European business of Alvogen. White & Case advised Alvogen on the deal, which is expected to close in the first quarter of 2020.
Zentiva is an international pharmaceutical company that is based in Prague and focuses on developing, manufacturing, and marketing generic pharmaceutical products.
Alvogen CEE markets over 200 generic and over-the-counter products across multiple therapeutic areas in 14 markets, including Russia, Romania, Bulgaria, Hungary, Poland, and the Balkans.
The Freshfields team included Partners James Scott, Helen Lethaby, Alan Ryan, and Jochen Dieselhorst, Senior Associate Vincent Bergin, and Principal Associate Lutz Dralle.
CMS' Prague-based team included Managing Partner Helen Rodwell, Senior Associates Frances Gerrard and Marketa Frankova, Associates Pavel Drimal and Tristan O’Connor, and Trainee Solicitor Moritz Kopka. The team also had support from Sofia-based Partner Atanas Bangachev, Bucharest-based Partner Horea Popescu and Senior Associate Claudia Popescu, Budapest-based Partner Aniko Kircsi and Senior Associate Peter Toth, Warsaw-based Partner Rafal Zwierz and Senior Associate Gregorz Paczek, Moscow-based Consultant David Cranfield and Senior Associate Maxim Gubanov, and London-based Senior Associate John Markham and Associate Madeeha Anthony.
White & Case's London-based team included Partners Steven Worthington, Lucy Bullock, Lindsey Canning, Martin Forbes, Marc Israel, and Peita Menon, Counsel Paul Harrington, and Associates Katarina Ward, Benjamin Morrison, James Turner, Jean Renaldy, and Oliver Alsop.
Editor's Note: After this article was published Romania's Bondoc si Asociatii announced that it had worked alongside White & Case in advising Alvogen on the sale of its CEE business to the Zentiva group.